Profound Medical Corp. SEC filings document regulatory disclosures for a commercial-stage medical device company focused on interventional MRI procedures. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD disclosures, furnished press releases, revenue guidance and business updates tied to TULSA-PRO®, the TULSA Procedure™ and Sonalleve®.
The filing record also includes clinical and commercial disclosure categories, such as CAPTAIN trial updates, scientific-meeting presentations and TULSA Procedure adoption milestones. Governance filings record director changes and board appointments, while exchange-act cover disclosures identify the company’s common shares registered on Nasdaq under the PROF symbol.
Profound Medical Corp. furnished an update on its recent performance by reporting that it issued a press release with unaudited financial results for the three- and six-month periods ended June 30, 2025. The company also used the release to provide a broader business update.
The press release is attached as Exhibit 99.1 and is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced. This 8-K is a disclosure vehicle pointing investors to that detailed financial and operational information.